pharma · Primary Sclerosing Cholangitis (PSC) · No medical condition.
Dr. Falk Pharma
Dr. Falk Pharma GmbH
Dr. Falk Pharma clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE
- Employees
- 399
- Programs
- 11
- Drugs
- 15
- Patents
- 0
Dr. Falk Pharma projects
11 ClinicalTrials.gov programs sponsored by Dr. Falk Pharma.
Dr. Falk Pharma has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BUL-8/EEA
Dr. Falk Pharma GmbH
eosinophilic esophagitis
1 trial -
NUC01, Placebo to NUC01
Dr. Falk Pharma GmbH
primary sclerosing cholangitis (PSC)
1 trial -
NUT01
Dr. Falk Pharma GmbH
Primary Sclerosing Cholangitis (PSC)
1 trial -
BUL-5/ESD
Dr. Falk Pharma GmbH
Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
1 trial -
Budenofalk 4 mg Zäpfchen, placebo to test
Dr. Falk Pharma GmbH
Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
1 trial -
CEC-013/CEL
Dr. Falk Pharma GmbH
Celiac Disease
1 trial -
NAT-19/GPX
Dr. Falk Pharma GmbH
Idiopathic or Diabetic Gastroparesis
1 trial -
CEC-012/BIO
Dr. Falk Pharma GmbH
No medical condition.
1 trial -
NAT-022/BIO
Dr. Falk Pharma GmbH
Idiopathic or diabetic gastroparesis
1 trial -
NAT-024/BIO
Dr. Falk Pharma GmbH
No medical condition.
1 trial -
NUC-011/BIO
Dr. Falk Pharma GmbH
Primary Sclerosing Cholangitis (PSC)
1 trial
Frequently asked questions
How many clinical projects does Dr. Falk Pharma have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.